Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
Do you offer resection of oligometastatic disease for patients with recurrent uterine serous carcinoma within the pelvis following initial treatment with adjuvant chemotherapy and vaginal cuff brachytherapy?
Related Questions
How do you classify extensive LVSI in endometrial cancer?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
How do you manage a patient with widely metastatic serous endometrial cancer whose disease is stable after completion of 6 cycles of chemotherapy + immunotherapy?
In light of new NCCN guidelines that state combination chemotherapy + pelvic RT should be reserved for endometrial cancer of at least stage IIIB, will you recommend EBRT in addition to chemotherapy for stage IIIA endometrial cancers?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
When treating endometrial cancer patients with a combination of chemotherapy and vaginal cuff brachytherapy, when do you deliver cuff brachy?
How would you treat recurrent endometrial carcinoma with a presentation of inguinal and external iliac adenopathy?
Would you consider the addition of trastuzumab to carboplatin/paclitaxel for an advanced uterine carcinosarcoma that stains HER2 IHC 3+ in the carcinomatous components but IHC 0 in the sarcomatous regions?
Would you incorporate a PARP inhibitor into the management of a patient with endometrial cancer with a germline or somatic BRCA mutation?
Does the path length of vaginal cuff cylinder brachytherapy treatment as adjuvant therapy for endometrial cancer vary based on histology (serous, etc)?